Comparison of HER2-Targeted Antibodies for Fluorescence-Guided Surgery in Breast Cancer
Molecular Imaging, 2021 Background. Although therapeutic advances have led to enhanced survival in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer, detection of residual disease remains challenging.
Solmaz AghaAmiri +8 more
doaj +1 more source
Porcine sialoadhesin (CD169/Siglec-1) is an endocytic receptor that allows targeted delivery of toxins and antigens to macrophages. [PDF]
PLoS ONE, 2011 Sialoadhesin is exclusively expressed on specific subpopulations of macrophages. Since sialoadhesin-positive macrophages are involved in inflammatory autoimmune diseases, such as multiple sclerosis, and potentially in the generation of immune responses ...
Peter L Delputte +9 more
doaj +1 more source
Frontiers in Pharmacology, 2022 Immune checkpoint mechanisms are important molecular cell systems that maintain tolerance toward autoantigens in order to prevent immunity-mediated accidental damage.
Andrea Zanello +4 more
doaj +1 more source
Management of HER2-Low Metastatic Breast Cancer: A Comprehensive Statement by an Expert Group from the Middle East and Africa Region [PDF]
Middle East Journal of CancerApproximately 50 to 67% of breast cancers (BCs), traditionally categorized as human epidermal growth factor receptor 2 (HER2)-negative, but demonstrating low HER2 expression, are now being defined as a new HER2-low subset or HER2-low category of BC.
Shaheenah Dawood +9 more
doaj +1 more source
Antibody-Drug Conjugates: Functional Principles and Applications in Oncology and Beyond
Vaccines, 2021 In the era of precision medicine, antibody-based therapeutics are rapidly enriched with emerging advances and new proof-of-concept formats. In this context, antibody-drug conjugates (ADCs) have evolved to merge the high selectivity and specificity of ...
Charalampos Theocharopoulos +4 more
doaj +1 more source
Herceptin-Geldanamycin Immunoconjugates [PDF]
Cancer Research, 2004 Abstract The efficacy of monoclonal antibodies (mAbs) as single agents in targeted cancer therapy has proven to be limited. Arming mAbs with a potent toxic drug could enhance their activity. Here we report that conjugating geldanamycin (GA) to the anti-HER2 mAb Herceptin improved the activity of Herceptin.
Raya Mandler +4 more
openaire +1 more source
Antibody-drug conjugates in treating older patients suffering from cancer: what is the real value?
Human Vaccines & Immunotherapeutics, 2021 Immunotherapeutic drugs and target therapies have represented an epochal change in treating cancer patients. They represent an attractive option in oncologists’ armamentarium, particularly if we consider the optimal balance between efficacy and toxicity.
Gianluca Perego +3 more
doaj +1 more source
Electrochemical Immunosensing of ST2: A Checkpoint Target in Cancer Diseases
Biosensors, 2021 A magnetic beads (MB)-involved amperometric immunosensor for the determination of ST2, a member of the IL1 receptor family, is reported in this work.
Rebeca M. Torrente-Rodríguez +8 more
doaj +1 more source
DOTA-functionalized polylysine: a high number of DOTA chelates positively influences the biodistribution of enzymatic conjugated anti-tumor antibody chCE7agl. [PDF]
PLoS ONE, 2013 Site-specific enzymatic reactions with microbial transglutaminase (mTGase) lead to a homogenous species of immunoconjugates with a defined ligand/antibody ratio.
Jürgen Grünberg +6 more
doaj +1 more source
Pharmaceuticals, 2021 Metastatic castration-resistant prostate cancer is today incurable. Conventional imaging methods have limited detection, affecting their ability to give an accurate outcome prognosis, and current therapies for metastatic prostate cancer are insufficient.
Joanna Strand +5 more
doaj +1 more source